Sunday, February 23, 2020

Sunday, February 23, 2020

Latest News

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.: Announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA.

ALLERGAN, PLC: Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older

FDA Health News